TAO Synergies (TAOX) Price to Sales (2025 - 2026)
TAO Synergies' (TAOX) quarterly Price to Sales came in at 314.52 in Q2 2026, down 89.86% on a YoY basis from 3101.17 in Q2 2025, and up 187.61% quarter-over-quarter from 109.36 in Q1 2026.
Powered by 
Analysis
TAO Synergies (TAOX) Price to Sales (2025 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Price to Sales for 2 consecutive years, with 314.52 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Price to Sales fell 89.86% year-over-year to 314.52; the trailing twelve-month figure through Jun 2026 stood at 36.08 (changed N/A YoY), and the FY2025 full-year result was 40.61, changed N/A from the prior year.
- Price to Sales improved to 314.52 in Q2 2026 per TAOX's latest filing, from 109.36 in the prior quarter.
- Across five years, Price to Sales topped out at 3101.17 in Q2 2025 and bottomed at 82.12 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn |
| 10 | TAO Synergies | 30.90 Mn | 30.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 314.52 |
| Mar 31, 2026 | 109.36 |
| Dec 31, 2025 | 132.40 |
| Sep 30, 2025 | 82.12 |
| Jun 30, 2025 | 3,101.17 |